Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Evolving Role of Aromatase Inhibitors in the Adjuvant Breast Cancer Setting

The Evolving Role of Aromatase Inhibitors in the Adjuvant Breast Cancer Setting Third-generation aromatase inhibitors (AIs) have shown at least equivalent or superior efficacy to tamoxifen in the first-line treatment of women with hormone-dependent metastatic breast cancer. Similar results have been obtained in the neoadjuvant setting. These studies suggested that AIs may also have significant efficacy in the adjuvant setting, and evaluation against tamoxifen is ongoing. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

The Evolving Role of Aromatase Inhibitors in the Adjuvant Breast Cancer Setting

American Journal of Cancer , Volume 2 (1) – Aug 10, 2012

Loading next page...
 
/lp/springer-journals/the-evolving-role-of-aromatase-inhibitors-in-the-adjuvant-breast-AbERiTXEPJ

References (34)

Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302001-00003
Publisher site
See Article on Publisher Site

Abstract

Third-generation aromatase inhibitors (AIs) have shown at least equivalent or superior efficacy to tamoxifen in the first-line treatment of women with hormone-dependent metastatic breast cancer. Similar results have been obtained in the neoadjuvant setting. These studies suggested that AIs may also have significant efficacy in the adjuvant setting, and evaluation against tamoxifen is ongoing.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.